Last reviewed · How we verify

SEVOFLURANE

FDA-approved approved Small molecule Quality 18/100

Sevoflurane is a marketed anesthetic agent used for the induction and maintenance of general anesthesia, holding a significant position in the anesthetic market. Its key strength lies in its well-established use and safety profile, supported by a key composition patent expiring in 2028. The primary risk is the potential increase in competition as the patent expiration approaches, which could impact market share and revenue.

At a glance

Generic nameSEVOFLURANE
Drug classGeneral Anesthetic [EPC]
ModalitySmall molecule
PhaseFDA-approved
First approval1995

Approved indications

Common side effects

Serious adverse events

Drug interactions

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
FDA labelMechanism, indications, dosing, boxed warnings, drug interactions
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: